Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 2
---
 we sell securities pursuant to this prospectus, we will provide in a supplement to this prospectus the price and any other material
terms of any such offering. We may also authorize one or more free writing prospectuses to be provided to you in connection with each
offering. Any prospectus supplement and related free writing prospectuses may also add, update or change information contained in the
prospectus. You should read this prospectus, any applicable prospectus supplement and related free writing prospectuses, as well as the
documents incorporated by reference or deemed incorporated by reference into this prospectus, carefully before you invest in the securities.

The Common Shares are traded
on the Nasdaq Capital Market under the symbol “NLSP.” On February 7, 2025, the last reported sale price of our Common Shares
on the Nasdaq Capital Market was $1.87 per share.

On February 7, 2025, the aggregate
market value of our Common Shares held by non-affiliates was approximately $5,649,925 based on 3,021,350 Common Shares outstanding and
a per share price of $1.87 based on the closing sale price of our Common Shares on such date. We have offered and sold $2,536,660 of our
securities pursuant to General Instruction I.B.5 on Form F-3 during the prior 12 calendar month period that ends on and includes the date
of this prospectus.

We are an emerging growth company, as defined in
the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and are subject to reduced public company reporting requirements.

Investing in the securities involves a high degree
of risk. Risks associated with an investment in the securities will be described in any applicable prospectus supplement and are and will
be described in certain of our filings with the Securities and Exchange Commission, or SEC, as described in “Risk Factors”.

The securities may be sold directly by us to investors,
through agents designated from time to time or to or through underwriters or dealers, or through a combination of such methods, on a continuous
or delayed basis. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution”
in this prospectus. If any agents or underwriters are involved in the sale of the securities with respect to which this prospectus is
being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-all